GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Glaxo (GSK) delivered earnings and revenue surprises of 11.32% and 4.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

An improved long-term sales target today revitalised GSK shares after their dismal 2024. The confidence in GSK’s drugs ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

As we mentioned on Tuesday, the majority of companies on the S&P 500 that have reported earnings, have beaten estimates, and ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

GSK (LON: GSK) has issued an update which inevitably reflects the difficulties faced in the last year, while also providing a host of reasons to be more upbeat on future prospects. Concerns over the ...